department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Toujeo Max Solostar · pharmadog

pharmadog
drugs
Toujeo Max Solostar

drug

patient view →

Toujeo LA

Marketedupdated 2mo ago

by Sanofi-Aventis US LLC

Approved

community read0 votes

Protein drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.

indications

investigational

Type 2 Diabetes

all catalysts(12)

approval · 12

view all 12 catalysts →

News(0)

no news has mentioned this drug yet

brand

Toujeo Max Solostar

generic

insulin glargine

MOA

Insulin receptor agonist

indication

Type 1 Diabetes (Juvenile Diabetes)

phase

marketed

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagApproval24 co-mentions · 12 sources
drugSOLIQUA 100/3324 co-mentions · 12 sources
druginsulin glargine LA12 co-mentions · 12 sources
drug(insulin glargine + lixisenatide)12 co-mentions · 12 sources
drugAbasaglar12 co-mentions · 12 sources
druginsulin12 co-mentions · 12 sources
company$SNYSanofi12 co-mentions · 12 sources
company$SNYNFSanofi12 co-mentions · 12 sources

Trials studying Toujeo LA

phase3A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Beforecompletedn=1,085
phase3A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetesrecruitingn=877
phase3A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)completedn=485
phase3A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Riskcompletedn=2,749
phase3A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetescompletedn=429
phase4A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitusactive not recruitingn=105
phase4iGlarLixi CGM Study in Chinese T2D Individuals After OADsrecruitingn=678
phase3A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetescompletedn=401

more trials →